Coronary artery disease (CAD) is a major public health problem all over the world. Therefore, the search for new biomarkers, which could detect early stages of CAD and improve survival, is of highest priority. In the present study, we investigated the association between content as well as composition of both soluble fibrin monomer complexes (SFMCs) and vitamin K-dependent proteins (VKDPs) with adverse cardiovascular events.
A total of 88 subjects with CAD, as well as 20 individuals free from cardiovascular disease were studied. Patients were classified into 4 groups: group I – patients with stable angina (n=25), group II – patients with unstable angina pectoris of new onset (n=17), group III – patients with progressive unstable angina (n=28), and group IV – patients with myocardial infarction (n=18). Concentrations of fibrinogen and SFMCs in blood plasma were measured by using commercial kits (Renam, Rassia). ELISA technique was used to determine plasma prothrombin. Isolation of SFMCs and VKDPs from blood plasma was performed according to the procedures described previously [1, 2]. Size-exclusion chromatography on Superdex 200 pg column (HiLoad 16/60, Healthcare Life Sciences) was used to identify and characterize separate fractions present in total pool of SFMCs and VKDPs. The appearance of corresponding peaks (protein fractions with particular molecular weight) was monitored by means of UV detector of BioLogic LP chromatographer (BioRad, USA). The peak areas were calculated using OriginLab (v 9.1).
According to the results obtained, there were no significant differences between fibrinogen concentrations in plasma of patients with angina pectoris, and control subjects. However, patients suffering from myocardial infarction have been shown to have increased fibrinogen values. Our findings revealed that prothrombin levels were similar in plasma of all groups of patients with CAD, and were significantly decreased compared to control subjects. Our results showed that plasma SFMC concentrations were increased 12-fold in both groups of patients with unstable angina as well as patients with myocardial infarction, compared to healthy volunteers. It should be note that concentration of SFMC in plasms of patients suffering from stable angina was remarkably lower compared to other CAD groups but still significantly higher than in control subjects. Additionally, the development of CAD was accompanied by the changes in both quantity and quality of SFMC composition, compared to that of healthy subjects. Thus, SFMCs with higher molecular weight (approximately 670-690 kDa) were identified in plasma of patients of all CAD groups, in contrast to control group. Our results also demonstrated that 80% of total VKDPs pool in plasma of healthy subjects was represented by protein fraction with molecular weight of 55-70 kDa, while in CAD patients the content of this particular fraction was decreased. Simultaneously, the level of VKDPs with molecular weight of 145-150 kDa were elevated in all CAD groups. Furthermore, the level of these high molecular weight complexes appears to corelate with more severe form of CAD.
Overall, our results indicate that both SFMCs and VKDPs have a potential role in CAD development and progression. Clearly, more studies are needed to evaluate the relationship between circulating SFMCs as well as VKDPs, and severity of cardiovascular events in the CAD patients.